Axxess Pharma, Inc. Retains Former Wyeth Laboratories Assistant to the Medical Director

MARKHAM, ON--(Marketwire - October 14, 2010) - Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they have retained former Wyeth Laboratories employee, Christopher Sequeira as Medical Director.

Mr. Sequeira has a lengthy background in the pharmaceutical industry. Prior to joining Axxess Pharma, Mr. Sequeira worked at Wyeth Laboratories in the medical department assisting the Medical Director. Wyeth Laboratories is the world's largest research based pharmaceutical company and is currently the world leader in the research and development of pharmaceutical and health care products.

Ms. Sequeira's primary responsibilities for Axxess Pharma will be:

1.  Development of new pharmaceutical products and arranging clinical trials
2.  Acquiring and licensing new products 
3.  Working with Health Canada to approve all Axxess Pharma products 
4.  Discussing medical and professional queries with hospitals, pharmacies,
    general practitioners and sales force. 

"We are pleased to have Christopher Sequeira join Axxess Pharma. His experience and connections at Wyeth Laboratories will be of great help for our company. Mr. Sequiera has also taken over the responsibilities of former employee Dr. W. Ronald Porter," stated Derek Sequeira, President/CEO.

For more information, please contact Investor Relations at (973) 351-3868.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Safe Harbor

Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.